Plixorafenib

Phase 2Small molecule

FFore Biotherapeutics

Plixorafenib is one of 4 small molecule programs targeting BRAF. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BRAFRecruiting

BRAFPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in BRAF

#DrugCompanyPhaseTrials

Cotellic

Roche

Phase 3

2 2

Tecentriq

Roche

Phase 2

1 3

Avastin

Roche

Phase 2

1 4

Plixorafenib

FFore Biotherapeutics

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Not yet recruiting

Glioblastoma Multiforme

NCT07908147

Q2 2028

Phase 1Recruiting

BRAF V600E Mutation

NCT06610682

Q4 2028

Phase 2Recruiting

BRAF

NCT05503797

Clinical

Trials by Indication[1]

Tics1 trial

A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Volunteers.

Completed·FFore Biotherapeutics·Phase 1·NCT06385119·28 enrolled

Glioblastoma Multiforme1 trial

Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients (BRAid GBM) Pilot Study

Not yet recruiting·OOlivia Newton-John Cancer Research Institute·Phase 1·NCT07908147·12 enrolled

BRAF V600E Mutation1 trial

A Trial to Evaluate Deoxyribonucleic) in BRAF (V-raf Murine Sarcoma Viral Oncogene Homolog B1)-Altered Glioma During Treatment With Plixorafenib Alone or With Retifanlimab

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT06610682·24 enrolled

BRAF1 trial

A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations

Recruiting·FFore Biotherapeutics·Phase 2·NCT05503797·254 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Plixorafenib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Plixorafenib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Plixorafenib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fore Biotherapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFore Biotherapeutics

Plixorafenib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q2 2028

Q4 2028

Trials by Indication[1]

Tics1 trial

Glioblastoma Multiforme1 trial

BRAF V600E Mutation1 trial

BRAF1 trial

References

Drug Info

Quick Facts

Related News